Taysha Gene Therapies, Inc. (TSHA)
Nasdaq: TSHA · Biological Products, (No Diagnostic Substances) · Dallas, TX · filing with the SEC since 2020
Who owns Taysha Gene Therapies, Inc.
As filed with the SECHolders of 5% or more
7
RA Capital Management, L.P. holds 9.9% of Common Stock, $0.00001 par value per share, as its SCHEDULE 13G/A filed Aug 14, 2026 says.
Directors and officers
7
report now, of 11 people on the record since 2020. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 7 named at left.
Holders of 5% or moreshare of the class, as filed
RA Capital Management, L.P.
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, $0.00001 par value per share · 9.9% in Nov 14, 2025
Paul B Manning
SCHEDULE 13D/A · filed Jun 3, 2025 · Common Stock, $0.00001 par value per share
RTW Investments, LP
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, par value $0.00001 per share · 8.3% in Feb 17, 2026
Blackrock, Inc.
SCHEDULE 13G/A · filed Jan 21, 2026 · Common Stock · 5.2% in Jul 16, 2025
Vestal Point Capital, LP
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, par value $0.00001 per share · 5% in Feb 17, 2026
Morgan Stanley
SCHEDULE 13G/A · filed Aug 13, 2026 · Common Stock · 6.7% in Aug 6, 2025
Goldman Sachs Group Inc.
SCHEDULE 13G · filed Jul 3, 2025 · Common Stock, par value $0.00001 per share
Fmr LLC
SCHEDULE 13G/A · filed Feb 5, 2026 · COMMON STOCK · reported falling below 5%, from 6.2% in Aug 6, 2025
Octagon Capital Advisors LP
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock, $0.00001 par value · reported falling below 5%, from 5.1% in Feb 5, 2025
What TSHA reports owning in othersstakes of 5% or more, and other ties
Taysha Gene Therapies, Inc. reports no stake in another company in the record.
Insider tradesForm 4
12sales
0purchases
3sales on a scheduled plan
3people selling
$6.7Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window3 of 13 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Nagendran Sukumar | President and Head of R&D | 7 | $5.3M | 3 | 0 | $0 |
| Nolan Sean P. | Chief Executive Officer | 2 | $800,000 | 0 | 0 | $0 |
| Alam Kamran | CHIEF FINANCIAL OFFICER | 3 | $500,000 | 0 | 0 | $0 |